Patents by Inventor Ja Young Kim-Muller

Ja Young Kim-Muller has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of aldehyde dehydrogenase as biomarker for beta-cell dysfunction and loss
    Patent number: 10732173
    Abstract: Methods are provided for obtaining a sample of ? cells from an isolated donor pancreas or isolated pancreatic islets and analyzing the sample using flow cytometry to determine the percentage of ? cells in the sample that express detectable levels of ALDH1 A3. If the percentage of ALDH1 A3-expressing ? cells in the sample is about 3% or lower, then it is possible to determine that the pancreas or islets are healthy enough for implantation into a subject, and implanting the pancreas or islets. If the percentage of ALDH1 A3-expressing cells is above about 5%, then it is determined that the pancreas or islets are not suitable for implantation into the subject and discarding the pancreas or islets. Isolated non-insulin-producing or low-insulin-producing pancreatic beta cells are also provided.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: August 4, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Domenico Accili, Ja Young Kim-Muller
  • USE OF ALDEHYDE DEHYDROGENASE AS BIOMARKER FOR BETA-CELL DYSFUNCTION AND LOSS
    Publication number: 20190265229
    Abstract: Methods are provided for obtaining a sample of ? cells from an isolated donor pancreas or isolated pancreatic islets and analyzing the sample using flow cytometry to determine the percentage of ? cells in the sample that express detectable levels of ALDH1 A3. If the percentage of ALDH1 A3-expressing ? cells in the sample is about 3% or lower, then it is possible to determine that the pancreas or islets are healthy enough for implantation into a subject, and implanting the pancreas or islets. If the percentage of ALDH1 A3-expressing cells is above about 5%, then it is determined that the pancreas or islets are not suitable for implantation into the subject and discarding the pancreas or islets. Isolated non-insulin-producing or low-insulin-producing pancreatic beta cells are also provided.
    Type: Application
    Filed: September 15, 2016
    Publication date: August 29, 2019
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Domenico Accili, Ja Young Kim-Muller